Wednesday, February 20, 2019

Trovagene Inc. (TROV)

Room for improvement in early prostate cancer data.

TrovaGene Inc is a
US-based life science company which focuses on the development and
commercialization of a proprietary molecular genetic detection technology for
use in pharmaceutical development, clinical research and medical testing across
a variety of clinical disciplines, including oncology and virology. 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

RATING: OUTPERFORM

• ASCO GU Data
  Presentations. The company presented early unfavorable data from the Phase 2 Study of Onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer at the Genitourinary Cancers Symposium on February 14.  The clinical benefit  in patients was determined by the prostate-specific antigen (PSA) level and reduction was observed only transiently.
• Adjusted Dosing Schedule. We believe the adjustment in dosing schedule and levels is not uncommon in early stages of drug development, The company intends to open a second arm, reducing the dose cycle to 14 days from 21 days t…
  
  
  GO TO FULL REPORT
  
  
  

  
  Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.